 |
volanesorsen sodium, apolipotrotein C-III antisense oligonucleotide |
|---|---|
| Trade Name | |
| Orphan Indication | Hyperlipoproteinemia type 1 |
| USA Market Approval | USA |
| USA Designation Date | 2015-06-23 00:00:00 |
| Sponsor | Akcea Therapeutics, Inc.;55 Cambridge Parkway, Suite 100;Cambridge, Massachusetts, 02142 |
